BELLUSCURA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.75 GBX | 0.00% |
|
-3.12% | -66.30% |
| 04-02 | Belluscura sees financial hit from delay to closing TMT acquisition | AN |
| 04-02 | AIM WINNERS & LOSERS: 88 Energy finds oil at Hickory-1; Redx to delist | AN |
| Sales 2023 * | 1.85M 148M | Sales 2024 * | 18.5M 1.48B | Capitalization | 15.93M 1.27B |
|---|---|---|---|---|---|
| Net income 2023 * | -11M -878M | Net income 2024 * | -4M -319M | EV / Sales 2023 * | 8.45 x |
| Net cash position 2023 * | 300K 23.95M | Net cash position 2024 * | 600K 47.9M | EV / Sales 2024 * | 0.83 x |
| P/E ratio 2023 * |
-1.25
x | P/E ratio 2024 * |
-3.58
x | Employees | 24 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 51.92% |
More Fundamentals
* Assessed data
More news
More recommendations
| 1 week | -3.12% | ||
| Current month | -58.11% | ||
| 1 month | -58.11% | ||
| 3 months | -62.20% | ||
| 6 months | -71.30% | ||
| Current year | -66.30% |
1 week
7.00
8.50
1 month
7.0015.00
Current year
7.0027.00
1 year
7.0052.00
3 years
7.00152.00
5 years
7.00152.00
10 years
7.00152.00
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Rauker
CEO | Chief Executive Officer | - | 17/08/16 |
Simon Neicheril
DFI | Director of Finance/CFO | 65 | 02/10/23 |
Brian Brown
CTO | Chief Tech/Sci/R&D Officer | - | 20/04/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ric Piper
BRD | Director/Board Member | 71 | 27/05/21 |
David Poutney
BRD | Director/Board Member | 71 | 27/05/21 |
Adam Reynolds
CHM | Chairman | 59 | 20/04/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 7.75 | 0.00% | 99,055 |
| 25/04/24 | 7.75 | 0.00% | 74,954 |
| 24/04/24 | 7.75 | +3.33% | 21,108 |
| 23/04/24 | 7.5 | -3.23% | 684,922 |
| 22/04/24 | 7.75 | -3.12% | 592,192 |
Delayed Quote London S.E., April 26, 2024 at 04:35 pm
More quotes
Belluscura PLC is a United Kingdom-based medical device developer company. The Company is focused on developing lightweight and portable oxygen enrichment technology. The Company's product X-PLOR, is a modular portable oxygen concentrator. The X-PLOR is lightweight, specifically designed to replace metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLOR can deliver up to 95% pure oxygen to patients 24 hours a day, seven days a week. The Company is focused on developing medical devices who suffer from chronic lung diseases, such as the Chronic Obstructive Pulmonary Disease (COPD), respiratory distress caused by COVID-19, and many other respiratory disorders. It is also focused on developing, licensing and manufacturing portable oxygen concentrators for use in treating lung diseases with its oxygen platform technologies, to include recreational and industrial oxygen concentrators, wound care devices, drug delivery devices and more.
Calendar
01/09/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0965
USD
Average target price
0.4652
USD
Spread / Average Target
+381.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -66.30% | 15.93M | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- BELL Stock
